Registered Office
Shortwave Life Sciences plc is incorporated in England and Wales under the Companies Act 2006 with the registration number 13351629. The main country of operation is The United Kingdom.
Shortwave Life Sciences Plc
124 City Road, London, EC1V 2NX
United Kingdom
Company Secretary
Mildwaters Consulting LLP
Walton House, 25 Bilton Rd, Rugby,
CV22 7AG, United Kingdom
Bankers
Peterhouse Capital Limited
80 Cheapside, London,
EC2V 6DZ, United Kingdom
AQSE Corporate Adviser and Broker
Peterhouse Capital Limited
80 Cheapside, London,
EC2V 6DZ, United Kingdom
Company Lawyers
Hill Dickinson LLP
The Broadgate Tower, 20 Primrose St, London,
EC2A 2EW, United Kingdom
Registrars
Neville Registrars Limited
Neville House, Steelpark Road, Halesowen,
B62 8HD, United Kingdom
Shares in Issue
The current number of ordinary shares in issue as of 8th July 2024 is 370,790,764. 18% of Psych Capital’s ordinary shares are held in public hands.
Options / Warrants
The Company has granted 10,000,000 share options over ordinary shares of the Company, as part of a new unapproved share option scheme, to existing directors and a further 1,694,915 to its advisors. Details of the Share Options can be found in the announcements dated 25 February 2024 and 6 June, 2024, respectively.
Warrant Holder: Peterhouse Capital Ltd
Total No. of Warrants: 14,501,667
Exercise Price: £0.05
Period: Up to the 5th anniversary of Admission
Restrictions on Share Transfer
Ordinary Shares are freely transferrable
Significant Shareholders
Percentage of issued share capital on Admission
Prohibition Holdings Limited – 90,000,000
Oscillate plc – 46,840,384
Peterhouse Capital Limited –20,480,469
William Potts – 10,731,233
Robert Reid – 10,528,210
Rivki Stern – 10,798,920 Roy Kait – 8,401,696
The Directors are committed to maintaining high standards of corporate governance, and, so far as is practicable given the Company’s size and nature, to comply with the QCA Code.
The Board holds at least six board meetings a year and will also hold timely board meetings as and when issues arise which require its attention. The Board is responsible for the management of the business of the Company, setting the strategic direction of the Company.
The Board has 4 formally established committees – Remuneration, Audit, AQSE Rules Compliance and an Executive Committee. The Board has also established a Psychedelic Medicines Technical Advisory Board consisting of industry experts.
The Company has established Financial Position and Prospects procedures and adopted an anti-bribery and corruption policy.
The following pages of this website contain documents relating to Psych Capital Plc (the “Company”)..
The materials on these pages are provided for information purposes only.
By selecting ‘I confirm’ below, you will be deemed to have made this confirmation.
Corporate Documents
Click to download the relative documents
- Psych Capital - Admission Document (PDF for Download)
- Articles of Association (PDF for Download)
- Psych Capital PLC Annual Report and Accounts for the Year Ended 30 April 2022
- Psych Capital AGM Notice 2022
- Psych Capital PLC Annual Report and Accounts for the Year Ended 30 April 2023
- Shortwave Life Sciences PLC Annual Report and Accounts for the Year Ended 30 April 2024
Investor Information
124 City Road, London,
EC1V 2NX
United Kingdom
Tel: +442038387621
Email: info@shortwavelifesciences.com